MARKET

PULM

PULM

Pulmatrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.630
+0.080
+5.16%
After Hours: 1.700 +0.07 +4.29% 19:27 01/17 EST
OPEN
1.560
PREV CLOSE
1.550
HIGH
1.700
LOW
1.500
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
3.010
52 WEEK LOW
0.6103
MARKET CAP
32.59M
P/E (TTM)
-0.7424
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PULM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PULM News

  • Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement
  • PR Newswire.2d ago
  • PLUG, NIO among premarket gainers
  • Seeking Alpha - Article.01/06 14:17
  • Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies
  • PR Newswire.01/06 13:58
  • Pulmatrix Surges on License Agreement With Johnson & Johnson
  • Zacks.01/03 14:55

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About PULM

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.
More

Webull offers Pulmatrix Inc (PULM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.